{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with study vaccine. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the study vaccine or protocol-specified procedure was also an AE. The only solicited systemic AE was in response to results of daily oral temperature assessments. The participant or the parent/guardian of the participant will be asked to record the participant's oral temperature in the evening after each study vaccination and daily for 4 days after each study vaccination on VRC. The percentage of participants that had an AE due to an elevated oral temperature \\[(≥ 37.8 °C (100.0 °F)\\] was summarized.","groups":[{"description":"Participants received a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6","id":"OG000","title":"9vHPV Vaccine"}],"paramType":"NUMBER","populationDescription":"All participants that received at least 1 vaccination with 9vHPV vaccine and provided safety data at any time during the study.","reportingStatus":"POSTED","timeFrame":"Up to 5 days after any vaccination","title":"Percentage of Participants With a Solicited Systemic Adverse Event","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}